Cargando…

Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients

AIMS/INTRODUCTION: The relationship between pancreatic fatty infiltration and diabetes is widely known, whereas the causal relationship is not clear. Furthermore, it is uncertain whether pathogenesis of pancreatic fat is similar to that of liver fat. We aimed to clarify the contribution of this type...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishibashi, Chisaki, Kozawa, Junji, Hosakawa, Yoshiya, Yoneda, Sho, Kimura, Takekazu, Fujita, Yukari, Fukui, Kenji, Iwahashi, Hiromi, Shimomura, Iichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944841/
https://www.ncbi.nlm.nih.gov/pubmed/31240874
http://dx.doi.org/10.1111/jdi.13108
_version_ 1783485084564717568
author Ishibashi, Chisaki
Kozawa, Junji
Hosakawa, Yoshiya
Yoneda, Sho
Kimura, Takekazu
Fujita, Yukari
Fukui, Kenji
Iwahashi, Hiromi
Shimomura, Iichiro
author_facet Ishibashi, Chisaki
Kozawa, Junji
Hosakawa, Yoshiya
Yoneda, Sho
Kimura, Takekazu
Fujita, Yukari
Fukui, Kenji
Iwahashi, Hiromi
Shimomura, Iichiro
author_sort Ishibashi, Chisaki
collection PubMed
description AIMS/INTRODUCTION: The relationship between pancreatic fatty infiltration and diabetes is widely known, whereas the causal relationship is not clear. Furthermore, it is uncertain whether pathogenesis of pancreatic fat is similar to that of liver fat. We aimed to clarify the contribution of this type of fat to glucose metabolism in type 2 diabetes patients by cross‐sectional and longitudinal analyses. MATERIAL AND METHODS: A total of 56 patients with type 2 diabetes who had been hospitalized twice were analyzed. We evaluated the mean computed tomography values of the pancreas (P), liver (L) and spleen (S). Lower computed tomography values indicate a greater fat content. We defined indices of pancreatic or liver fat content as the differences between P or L and S. We assessed the associations among fat content for the two organs (P‐S, L‐S) and clinical parameters at the first hospitalization, and then analyzed the associations between these fat contents and changes in glycometabolic markers (the second data values minus the first). RESULTS: In the cross‐sectional study, P‐S negatively correlated with the increment of C‐peptide in the glucagon stimulation test (r = −0.71, P < 0.0001) and body mass index (r = −0.28, P = 0.034). L‐S negatively correlated with homeostasis model assessment of insulin resistance (r = −0.73, P < 0.0001), body mass index (r = −0.62, P < 0.0001) and some other obesity‐related indicators, but not with the increment of C‐peptide in the glucagon stimulation test. In the longitudinal study, P‐S positively correlated with the change of the increment of C‐peptide in the glucagon stimulation test (r = 0.49, P = 0.021). CONCLUSIONS: In type 2 diabetes patients, pancreatic fat was less associated with obesity‐related indicators than liver fat, but was more strongly associated with the longitudinal decrease in endogenous insulin‐secreting capacity.
format Online
Article
Text
id pubmed-6944841
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69448412020-01-09 Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients Ishibashi, Chisaki Kozawa, Junji Hosakawa, Yoshiya Yoneda, Sho Kimura, Takekazu Fujita, Yukari Fukui, Kenji Iwahashi, Hiromi Shimomura, Iichiro J Diabetes Investig Articles AIMS/INTRODUCTION: The relationship between pancreatic fatty infiltration and diabetes is widely known, whereas the causal relationship is not clear. Furthermore, it is uncertain whether pathogenesis of pancreatic fat is similar to that of liver fat. We aimed to clarify the contribution of this type of fat to glucose metabolism in type 2 diabetes patients by cross‐sectional and longitudinal analyses. MATERIAL AND METHODS: A total of 56 patients with type 2 diabetes who had been hospitalized twice were analyzed. We evaluated the mean computed tomography values of the pancreas (P), liver (L) and spleen (S). Lower computed tomography values indicate a greater fat content. We defined indices of pancreatic or liver fat content as the differences between P or L and S. We assessed the associations among fat content for the two organs (P‐S, L‐S) and clinical parameters at the first hospitalization, and then analyzed the associations between these fat contents and changes in glycometabolic markers (the second data values minus the first). RESULTS: In the cross‐sectional study, P‐S negatively correlated with the increment of C‐peptide in the glucagon stimulation test (r = −0.71, P < 0.0001) and body mass index (r = −0.28, P = 0.034). L‐S negatively correlated with homeostasis model assessment of insulin resistance (r = −0.73, P < 0.0001), body mass index (r = −0.62, P < 0.0001) and some other obesity‐related indicators, but not with the increment of C‐peptide in the glucagon stimulation test. In the longitudinal study, P‐S positively correlated with the change of the increment of C‐peptide in the glucagon stimulation test (r = 0.49, P = 0.021). CONCLUSIONS: In type 2 diabetes patients, pancreatic fat was less associated with obesity‐related indicators than liver fat, but was more strongly associated with the longitudinal decrease in endogenous insulin‐secreting capacity. John Wiley and Sons Inc. 2019-07-27 2020-01 /pmc/articles/PMC6944841/ /pubmed/31240874 http://dx.doi.org/10.1111/jdi.13108 Text en © 2019 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Ishibashi, Chisaki
Kozawa, Junji
Hosakawa, Yoshiya
Yoneda, Sho
Kimura, Takekazu
Fujita, Yukari
Fukui, Kenji
Iwahashi, Hiromi
Shimomura, Iichiro
Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
title Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
title_full Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
title_fullStr Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
title_full_unstemmed Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
title_short Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
title_sort pancreatic fat is related to the longitudinal decrease in the increment of c‐peptide in glucagon stimulation test in type 2 diabetes patients
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944841/
https://www.ncbi.nlm.nih.gov/pubmed/31240874
http://dx.doi.org/10.1111/jdi.13108
work_keys_str_mv AT ishibashichisaki pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT kozawajunji pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT hosakawayoshiya pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT yonedasho pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT kimuratakekazu pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT fujitayukari pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT fukuikenji pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT iwahashihiromi pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients
AT shimomuraiichiro pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients